A Study of Regorafenib in Advanced Pancreatic Cancer Patients
Status:
Completed
Trial end date:
2017-06-28
Target enrollment:
Participant gender:
Summary
This study tests regorafenib as a single agent in the treatment of metastatic pancreatic
cancer patients who have progressed after prior chemotherapy with gemcitabine. The prognosis
for these patients is particularly grim, no other standard treatment options exist, and novel
approaches are desperately needed.